Regulatory T cell-derived exosome (Treg-Exo) (Treg-Exo)

Regulatory T cell-derived exosomes (Treg-Exos) are specialized extracellular vesicles secreted by regulatory T cells that function as key mediators of systemic immune tolerance and homeostasis. These nano-sized vesicles encapsulate a diverse array of bioactive molecules, including inhibitory proteins like CTLA-4 and PD-L1, enzymes such as CD39 and CD73, and various regulatory microRNAs like miR-155 and miR-146a (Tung et al., 2018). Treg-Exos exert their immunomodulatory effects by transferring this cargo to pro-inflammatory immune cells, such as effector T cells (Th1, Th17) and dendritic cells, thereby inhibiting their activation, proliferation, and cytokine production (Okoye et al., 2014). This mechanism is essential for preventing autoimmune responses and dampening chronic inflammation. Currently, Treg-Exos are being investigated as a cell-free therapeutic strategy for treating autoimmune disorders, chronic inflammatory conditions, and transplant rejection, offering potential advantages over whole-cell Treg therapy in terms of stability, safety, and the ability to cross biological barriers (Smyth et al., 2013). However, therapeutic development faces challenges regarding the standardization of isolation methods and the risk of unintended broad immunosuppression.

Other names

Treg-derived extracellular vesicleTreg-EVRegulatory T cell exosomeTreg-derived nano-vesicle

Suppression of pro-inflammatory immune cell activation and proliferation through the delivery of inhibitory surface proteins (e.g., CTLA-4, PD-L1), enzymes (e.g., CD39, CD73), and regulatory microRNAs (e.g., miR-155, miR-146a).